Debating EGFR Inhibitors for Squamous Cell Lung Cancer Patients
Article
Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.
[powerpress]